DEFA14A: Brookdale Senior Living Seeks Shareholder Support Amidst Strategic Overhaul and Boardroom Battle
Proxy Statement
Brookdale Senior Living urges shareholders to vote for its director nominees at the upcoming 2025 Annual Meeting, highlighting strategic initiatives, improved financial guidance, and ongoing engagement with investor perspectives amidst a proxy contest with Ortelius.
Summary
- Brookdale Senior Living is seeking shareholder support for its eight director nominees at the 2025 Annual Meeting.
- The company is undergoing a strategic reframing, incorporating investor perspectives into its board and management team composition.
- Brookdale has transitioned its former CEO and is actively searching for a new CEO.
- The company has outlined key strategic priorities for 2025 and beyond.
- Brookdale has increased its annual guidance for 2025 RevPAR year-over-year growth to 5.00%-5.75% and Adjusted EBITDA to $440M $450M.
- Positive annual guidance for 2025 Adjusted Free Cash Flow is in the range of $30M-$50M.
- Two new independent directors with extensive industry knowledge have been appointed to the Board.
- A review of governance enhancements relating to director tenure has been launched.
- An evaluation of revisions to the performance-based long-term incentive awards program has begun.
- Brookdale is making headway on achieving its long-term goals of driving continued growth in profitable occupancy, RevPAR, and Adjusted EBITDA, while delivering steady free cash flow generation.
- The company's first quarter results and annual guidance raise are a testament to the significant momentum underway.
- Brookdale is executing on five key initiatives to deliver meaningful shareholder value: improving operating performance, optimizing the real estate portfolio, reinvesting capital, reducing leverage, and ensuring high-quality environments.
- Brookdale has made efforts to engage with Ortelius, a 1% shareholder, but claims these efforts have not been met in kind.
- The company believes replacing any of its nominees would impair the Board's ability to identify a new CEO and execute its strategy.
- Analysts support Brookdale's strategy and leadership changes, noting the company is well-positioned to enhance value for all shareholders.
- Shareholders are urged to vote for Brookdale's eight nominees on the BLUE proxy card.
Sentiment
Score: 7
Explanation: The document presents a generally positive outlook for Brookdale, highlighting improved financial guidance, strategic initiatives, and analyst support. However, the ongoing proxy contest and CEO transition introduce some uncertainty, preventing a higher sentiment score.
Positives
- Increased annual guidance for 2025 RevPAR and Adjusted EBITDA.
- Positive annual guidance for 2025 Adjusted Free Cash Flow.
- Appointment of two new independent directors with extensive industry knowledge.
- Solid first quarter results with positive Adjusted Free Cash Flow and occupancy gains.
- Analysts support Brookdale's strategy and leadership changes.
- The Board has established a clear and compelling strategy for creating shareholder value.
- Consolidated RevPAR was 18% higher in 2024 than 2019.
- Operating income per available unit was 8% higher in 2024 than 2019.
- Adjusted EBITDA Margin is higher than 2019 levels and is continuing to rise.
Negatives
- Ongoing proxy contest with Ortelius, indicating potential disagreement on company strategy and governance.
- CEO transition underway, creating uncertainty in leadership.
- Ortelius did not disclose details of any strategic plan for Brookdale until April 24.
- Ortelius refused to participate in Brookdale's refreshment process and allow interviews of its director nominees a month prior greatly inhibited the Board's ability to consider any of the Ortelius nominees when refreshing its composition.
Risks
- The proxy contest with Ortelius could lead to disruption and uncertainty.
- Failure to successfully identify and appoint a new CEO could negatively impact the company's strategic direction.
- The company's ability to achieve its financial targets is subject to various risks and uncertainties, including economic downturns, competition, and regulatory changes.
- Actions of activist stockholders, including as a result of the current proxy contest and any potential change of control of the Company or the Board.
Future Outlook
Brookdale anticipates continued growth in profitable occupancy, RevPAR, and Adjusted EBITDA, along with steady free cash flow generation. The company is focused on improving operating performance, optimizing its real estate portfolio, reinvesting capital, reducing leverage, and ensuring high-quality environments.
Management Comments
- The Board and management team are taking decisive action to launch the next stage of the Company's growth.
- We are incorporating investor perspectives into a reframing of our strategic landscape and the composition of the Board and management team.
- Brookdale's solid first quarter results and annual guidance raise are a testament to the significant momentum underway, and the Board and management team are committed to continuing to drive quantifiable change.
- We are operating with purpose and are confident in our ability to deliver strong financial results, generate significant and growing cash flow, and drive substantial shareholder value creation.
Industry Context
The document highlights Brookdale's positioning amidst demographic tailwinds and favorable supply and demand dynamics in the senior housing industry. The company aims to close the growth and valuation gap with peers through revitalizing existing communities and executing a growth strategy.
Comparison to Industry Standards
- The document mentions that Brookdale's post-COVID growth is in line with its peers.
- Deerfield believes demand for Brookdale's services will well outstrip supply in a few short years due to demographics alone.
- Deerfield believes that revitalizing existing communities and executing a growth strategy made possible through rising operating cash flows can allow the company to close the growth and valuation gap with peers.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| CEO | Former CEO | TBD | April 2025 | Transition |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Tenure | Launched a review of governance enhancements relating to director tenure | 2025 | TBD |
| Executive Compensation | Began an evaluation of revisions to the performance-based long-term incentive awards program | 2025 | TBD |
Stakeholder Impact
- Shareholders: The company aims to deliver sustained and compelling returns.
- Residents: Brookdale is focused on ensuring high-quality environments.
- Associates: The company is focused on ensuring high-quality environments.
Next Steps
- Shareholders are urged to vote for Brookdale's eight director nominees on the BLUE proxy card before the July 11, 2025 Annual Meeting.
- The company will continue its search for a new CEO.
- Brookdale will continue executing on its five key initiatives to deliver meaningful shareholder value.
Key Dates
| Date | Description |
|---|---|
| 2000 to 2001 | Ms. Warren served as Senior Vice President and Chief Financial Officer of Gaylord Entertainment Company |
| 2005 to September 2015 | Ms. Warren served as Chief Financial Officer of Capella Healthcare, Inc. |
| 2006 | Dr. Asher served in several executive roles with Ascension since 2006 |
| 2007 to 2017 | Mr. Wielansky served as a director of Isle of Capri Casinos, Inc. |
| 2008 | Ms. Freed is Senior Vice President of Sales, Trade Support and Service for Royal Caribbean International, having served in that role since 2008 |
| 2011 to 2015 | Dr. Asher served as Chief Medical Officer and Chief Integration Officer of MissionPoint Health Partners |
| 2013 until his departure | Mr. Hausman served as Managing Director for Onex Partners |
| 2014 to June 2023 | Ms. Mace served as the Chief Economist and Director of Research and Analytics at the National Investment Center for Seniors Housing & Care (NIC) |
| 2015 | Mr. Fioravanti was appointed CEO on January 1, 2023, after serving as President and Chief Financial Officer since 2015. |
| October 2015 through December 2020 | Ms. Warren served as Executive Vice President and Chief Operating Officer of WakeMed Health & Hospitals |
| 2016 to 2018 | Dr. Asher served as Chief Clinical Officer of its Ascension Care Management subsidiary |
| 2018 to 2023 | Dr. Asher served as the Chief Physician Executive and Senior Vice President of Sentara |
| February 2018 through December 2019 | Mr. Wielansky served as the Company's Non-Executive Chairman of the Board |
| April 2021 until June 2023 | Ms. Drayton served as the Chief Financial Officer of Quantum-Si Incorporated |
| January 1, 2023 | Mr. Fioravanti was appointed CEO |
| 2023 to May 2025 | Dr. Asher served as Executive Vice President and Chief Clinical Officer of Sentara Healthcare |
| June 2024 | Ms. Warren has served as Brookdale's Interim Chief Executive Officer, Chairman and a member of the Office of CEO since April 2025; after having served as the non-executive chairman since June 2024. |
| Until November 2024 | Ms. Warren served on the Board of Directors of TruBridge, Inc. |
| February 2025 | Mr. Hausman spent two decades with Onex Corporation, from 2004 to February 2025 |
| April 2025 | Ms. Warren has served as Brookdale's Interim Chief Executive Officer, Chairman and a member of the Office of CEO since April 2025 |
| April 2025 | Since April 2025, Mr. Hausman has been Managing Partner at MHJ Capital Partners. |
| May 6, 2025 | Brookdale Announces First Quarter 2025 Results and Increases Annual Guidance |
| May 14, 2025 | The Company filed its definitive proxy statement (the Definitive Proxy Statement) and a BLUE universal proxy card with the US. Securities and Exchange Commission (the SLC) on May 14, 2025 |
| May 15, 2025 | Shareholder Letter #1 |
| July 11, 2025 | Annual Meeting |
Keywords
proxy contest, director nominees, annual meeting, shareholder value, senior living, Brookdale, Ortelius, governance, RevPAR, EBITDA, occupancy
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.